AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Active, not recruiting · NCT05632328 · Registry updated 2026-07-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-07-09 | NCT05632328 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Agenus Inc. | 23 |
| Bruno Bockorny | 1 |
| Dana-Farber Cancer Institute | 324 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |